Pathophysiology of Proliferative Vitreoretinopathy in Retinal Detachment

Survey of Ophthalmology

Volumn 58, Issue 4, 2013, Pages 321-329

  Garweg, Justus G ^a   Tappeiner, Christoph ^a   Halberstadt, Markus ^a  

^a UNIVERSITY OF BERN   (Switzerland)

Author keywords

Diagnosis; Inflammation; Pathophysiology; Proliferative vitreoretinopathy; Risk factors; Tissue remodeling

Indexed keywords

ADENOSINE TRIPHOSPHATE; AUTOANTIBODY; BAX INHIBITOR 1 PROTEIN; CELL PROTEIN; CHEMOKINE; COLLAGEN; DNA; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 1BETA; LEPTIN; STEROID; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG;

APHAKIA; APOPTOSIS; ARTICLE; AUTOIMMUNITY; BLOOD RETINA BARRIER; CELL DAMAGE; CELL DEDIFFERENTIATION; CELL HYPOXIA; CELL MIGRATION; CELL PROLIFERATION; CELLULAR SECRETION; COLLAGEN SYNTHESIS; CYTOKINE RELEASE; DIABETIC RETINOPATHY; DNA POLYMORPHISM; FUNCTIONAL STATUS; GENETIC PREDISPOSITION; GENETIC RISK; GLIA; GLIOSIS; HEREDITY; HISTOPATHOLOGY; HUMAN; IMMUNE RESPONSE; INFLAMMATION; INTRAOPERATIVE PERIOD; MACROPHAGE; MICROENVIRONMENT; NEUROPROTECTION; NONHUMAN; NUTRITIONAL REQUIREMENT; PATHOPHYSIOLOGY; PATIENT IDENTIFICATION; PHOTORECEPTOR CELL; PIGMENT EPITHELIUM; PREOPERATIVE PERIOD; PRIORITY JOURNAL; PROTEIN EXPRESSION; RETINA DETACHMENT; RETINA ISCHEMIA; RETINA TEAR; SCAR FORMATION; TISSUE REPAIR; VITREORETINOPATHY; VITREOUS BODY; VITREOUS HEMORRHAGE; WOUND HEALING;

HUMANS; RETINAL DETACHMENT; RISK FACTORS; VITREORETINOPATHY, PROLIFERATIVE;

EID: 84879142645     PISSN: 00396257     EISSN: 18793304     Source Type: Journal    
DOI: 10.1016/j.survophthal.2012.12.004     Document Type: Article

References (105)

1. Asaria R.H., Kon C.H., Bunce C., et al. Adjuvant 5-fluorouracil and heparin prevents proliferative vitreoretinopathy: results from a randomized, double-blind, controlled clinical trial. Ophthalmology 2001, 108:1179-1183.
2. Asaria R.H.Y., Charteris D.G. Proliferative vitreoretinopathy: developments in pathogenesis and treatment. Compr Ophthalmol Update 2006, 7:179-185.
3. Asaria R.H.Y., Gregor Z.J. Simple retinal detachments: identifying the at-risk case. Eye (Lond) 2002, 16:404-410.
4. Bali E., Feron E.J., Peperkamp E., et al. The effect of a preoperative subconjuntival injection of dexamethasone on blood-retinal barrier breakdown following scleral buckling retinal detachment surgery: a prospective randomized placebo-controlled double blind clinical trial. Graefes Arch Clin Exp Ophthalmol 2010, 248:957-962.
5. Banerjee S., Savant V., Scott R.A.H., et al. Multiplex bead analysis of vitreous humor of patients with vitreoretinal disorders. Invest Ophthalmol Vis Sci 2007, 48:2203-2207.
6. Baudouin C., Gastaud P. [Vitreoretinal proliferation. II. Pathogenic hypotheses]. J Fr Ophtalmol 1994, 17:800-811.
7. Berger A.S., Cheng C.K., Pearson P.A., et al. Intravitreal sustained release corticosteroid-5-fluoruracil conjugate in the treatment of experimental proliferative vitreoretinopathy. Invest Ophthalmol Vis Sci 1996, 37:2318-2325.
8. Bonnet M., Guenoun S. Surgical risk factors for severe postoperative proliferative vitreoretinopathy (PVR) in retinal detachment with grade B PVR. Graefes Arch Clin Exp Ophthalmol 1995, 233:789-791.
9. Bonnet M. Clinical factors predisposing to massive proliferative vitreoretinopathy in rhegmatogenous retinal detachment. Ophthalmologica 1984, 188:148-152.
10. Broekhuyse R.M., Rademakers A.J., van Vugt A.H., et al. Autoimmune responsiveness to retinal IRBP, S-antigen and opsin in proliferative vitreoretinopathy. Exp Eye Res 1990, 50:197-202.
11. Burke J.M., Twining S.S. Vitreous macrophage elicitation: generation of stimulants for pigment epithelium invitro. Invest Ophthalmol Vis Sci 1987, 28:1100-1107.
12. Campochiaro P.A., Jerdan J.A., Glaser B.M., et al. Vitreous aspirates from patients with proliferative vitreoretinopathy stimulate retinal pigment epithelial cell migration. Arch Ophthalmol 1985, 103:1403-1405.
13. Campochiaro P.A., Jerdan J.A., Glaser B.M. Serum contains chemoattractants for human retinal pigment epithelial cells. Arch Ophthalmol 1984, 102:1830-1833.
14. Charteris D.G., Hiscott P., Grierson I., et al. Proliferative vitreoretinopathy. Lymphocytes in epiretinal membranes. Ophthalmology 1992, 99:1364-1367.
15. Charteris D.G., Hiscott P., Robey H.L., et al. Inflammatory cells in proliferative vitreoretinopathy subretinal membranes. Ophthalmology 1993, 100:43-46.
16. Charteris D.G., Sethi C.S., Lewis G.P., et al. Proliferative vitreoretinopathy-developments in adjunctive treatment and retinal pathology. Eye (Lond) 2002, 16:369-374.
17. Cheema R.A., Peyman G.A., Fang T., et al. Triamcinolone acetonide as an adjuvant in the surgical treatment of retinal detachment with proliferative vitreoretinopathy. Ophthalmic Surg Lasers Imaging 2007, 38:365-370.
18. Comer M.B., Newman D.K., George N.D., et al. Who should manage primary retinal detachments?. Eye (Lond) 2000, 14(Pt 4):572-578.
19. Cowley M., Conway B.P., Campochiaro P.A., et al. Clinical risk factors for proliferative vitreoretinopathy. Arch Ophthalmol 1989, 107:1147-1151.
20. Crosson L.A., Kroes R.A., Moskal J.R., et al. Gene expression patterns in hypoxic and post-hypoxic adult rat retina with special reference to the NMDA receptor and its interactome. Mol Vis 2009, 15:296-311.
21. Cui J.Z., Chiu A., Maberley D., et al. Stage specificity of novel growth factor expression during development of proliferative vitreoretinopathy. Eye (Lond) 2007, 21:200-208.
22. Curtin V.T., Fujino T., Norton E.W. Comparative histopathology of cryosurgery and photocoagulation. Observations on the advantages of cryosurgery in retinal detachment operations. Arch Ophthalmol 1966, 75:674-682.
23. Dieudonné S.C., La Heij E.C., Diederen R., et al. High TGF-beta2 levels during primary retinal detachment may protect against proliferative vitreoretinopathy. Invest Ophthalmol Vis Sci 2004, 45:4113-4118.
24. El-Ghrably I.A., Dua H.S., Orr G.M., et al. Intravitreal invading cells contribute to vitreal cytokine milieu in proliferative vitreoretinopathy. Br J Ophthalmol 2001, 85:461-470.
25. Elner S.G., Elner V.M., Jaffe G.J., et al. Cytokines in proliferative diabetic retinopathy and proliferative vitreoretinopathy. Curr Eye Res 1995, 14:1045-1053.
26. Erickson P.A., Fisher S.K., Anderson D.H., et al. Retinal detachment in the cat: the outer nuclear and outer plexiform layers. Invest Ophthalmol Vis Sci 1983, 24:927-942.
27. Gamulescu M.-A., Chen Y., He S., et al. Transforming growth factor beta2-induced myofibroblastic differentiation of human retinal pigment epithelial cells: regulation by extracellular matrix proteins and hepatocyte growth factor. Exp Eye Res 2006, 83:212-222.
28. Girard P., Mimoun G., Karpouzas I., et al. Clinical risk factors for proliferative vitreoretinopathy after retinal detachment surgery. Retina 1994, 14:417-424.
29. Glaser B.M., Cardin A., Biscoe B. Proliferative vitreoretinopathy. The mechanism of development of vitreoretinal traction. Ophthalmology 1987, 94:327-332.
30. Glaser B.M., Vidaurri-Leal J., Michels R.G., et al. Cryotherapy during surgery for giant retinal tears and intravitreal dispersion of viable retinal pigment epithelial cells. Ophthalmology 1993, 100:466-470.
31. Guérin C.J., Anderson D.H., Fariss R.N., et al. Retinal reattachment of the primate macula. Photoreceptor recovery after short-term detachment. Invest Ophthalmol Vis Sci 1989, 30:1708-1725.
32. Guidry C. The role of Müller cells in fibrocontractive retinal disorders. Prog Retin Eye Res 2005, 24:75-86.
33. Harada C., Mitamura Y., Harada T. The role of cytokines and trophic factors in epiretinal membranes: involvement of signal transduction in glial cells. Prog Retin Eye Res 2006, 25:149-164.
34. Heidenkummer H.P., Kampik A. [Comparative immunohistochemical studies of epiretinal membranes in proliferative vitreoretinal diseases]. Fortschr Ophthalmol 1991, 88:219-224.
35. Heidenkummer H.P., Messmer E.M., Kampik A. [Recurrent vitreoretinal membranes in intravitreal silicon oil tamponade. Morphologic and immunohistochemical studies]. Ophthalmologe 1996, 93:121-125.
36. Hinton D.R., He S., Jin M.L., et al. Novel growth factors involved in the pathogenesis of proliferative vitreoretinopathy. Eye (Lond) 2002, 16:422-428.
37. Hiscott P., Hagan S., Heathcote L., et al. Pathobiology of epiretinal and subretinal membranes: possible roles for the matricellular proteins thrombospondin 1 and osteonectin (SPARC). Eye (Lond) 2002, 16:393-403.
38. Hiscott P., Morino I., Alexander R., et al. Cellular components of subretinal membranes in proliferative vitreoretinopathy. Eye (Lond) 1989, 3(Pt 5):606-610.
39. Hiscott P., Sheridan C., Magee R.M., et al. Matrix and the retinal pigment epithelium in proliferative retinal disease. Prog Retin Eye Res 1999, 18:167-190.
40. Hiscott P.S., Grierson I., McLeod D. Retinal pigment epithelial cells in epiretinal membranes: an immunohistochemical study. Br J Ophthalmol 1984, 68:708-715.
41. Hollborn M., Francke M., Iandiev I., et al. Early activation of inflammation- and immune response-related genes after experimental detachment of the porcine retina. Invest Ophthalmol Vis Sci 2008, 49:1262-1273.
42. Iandiev I., Bringmann A., Wiedemann P. [Proliferative vitreoretinopathy-pathogenesis and therapy]. Klin Monbl Augenheilkd 2010, 227:168-174.
43. Kauffmann D.J., van Meurs J.C., Mertens D.A., et al. Cytokines in vitreous humor: interleukin-6 is elevated in proliferative vitreoretinopathy. Invest Ophthalmol Vis Sci 1994, 35:900-906.
44. Kirchhof B., Kirchhof E., Ryan S.J., et al. Vitreous modulation of migration and proliferation of retinal pigment epithelial cells invitro. Invest Ophthalmol Vis Sci 1989, 30:1951-1957.
45. Kirchhof B., Sorgente N. Pathogenesis of proliferative vitreoretinopathy. Modulation of retinal pigment epithelial cell functions by vitreous and macrophages. Dev Ophthalmol 1989, 16:1-53.
46. Kirchhof B. Strategies to influence PVR development. Graefes Arch Clin Exp Ophthalmol 2004, 242:699-703.
47. Kita T., Hata Y., Miura M., et al. Functional characteristics of connective tissue growth factor on vitreoretinal cells. Diabetes 2007, 56:1421-1428.
48. Koerner F., Merz A., Gloor B., et al. Postoperative retinal fibrosis-a controlled clinical study of systemic steroid therapy. Graefes Arch Clin Exp Ophthalmol 1982, 219:268-271.
49. Koerner F., Merz E., Wagner A., et al. [Proliferative vitreoretinopathy: relation to the extent of retinal detachment, size of retinal tears and coagulation surface]. Klin Monbl Augenheilkd 1988, 192:465-467.
50. Kon C.H., Occleston N.L., Aylward G.W., et al. Expression of vitreous cytokines in proliferative vitreoretinopathy: a prospective study. Invest Ophthalmol Vis Sci 1999, 40:705-712.
51. Kosnosky W., Li T.H., Pakalnis V.A., et al. Interleukin-1-beta changes the expression of metalloproteinases in the vitreous humor and induces membrane formation in eyes containing preexisting retinal holes. Invest Ophthalmol Vis Sci 1994, 35:4260-4267.
52. Körner F., Bohnke M. [Vitrectomy in proliferative vitreoretinopathy. Anatomical and functional results in 501 patients]. Klin Monbl Augenheilkd 1995, 206:239-245.
53. Krajewska M., Xu L., Xu W., et al. Endoplasmic reticulum protein BI-1 modulates unfolded protein response signaling and protects against stroke and traumatic brain injury. Brain Res 2011, 1370:227-237.
54. Kubay O.V., Charteris D.G., Newland H.S., et al. Retinal detachment neuropathology and potential strategies for neuroprotection. Surv Ophthalmol 2005, 50:463-475.
55. La Heij E.C., van de Waarenburg M.P., Blaauwgeers H.G., et al. Levels of basic fibroblast growth factor, glutamine synthetase, and interleukin-6 in subretinal fluid from patients with retinal detachment. Am J Ophthalmol 2001, 132:544-550.
56. Laqua H., Machemer R. Clinical-pathological correlation in massive periretinal proliferation. Am J Ophthalmol 1975, 80:913-929.
57. Lashkari K., Rahimi N., Kazlauskas A. Hepatocyte growth factor receptor in human RPE cells: implications in proliferative vitreoretinopathy. Invest Ophthalmol Vis Sci 1999, 40:149-156.
58. Lei H., Hovland P., Velez G., et al. A potential role for PDGF-C in experimental and clinical proliferative vitreoretinopathy. Invest Ophthalmol Vis Sci 2007, 48:2335-2342.
59. Lei H., Rheaume M.-A., Kazlauskas A. Recent developments in our understanding of how platelet-derived growth factor (PDGF) and its receptors contribute to proliferative vitreoretinopathy. Exp Eye Res 2010, 90:376-381.
60. Lesnik-Oberstein S.Y., Lewis G.P., Dutra T., et al. Evidence that neurites in human epiretinal membranes express melanopsin, calretinin, rod opsin and neurofilament protein. Br J Ophthalmol 2011, 95:266-272.
61. Lewis G.P., Betts K.E., Sethi C.S., et al. Identification of ganglion cell neurites in human subretinal and epiretinal membranes. Br J Ophthalmol 2007, 91:1234-1238.
62. Lewis G.P., Chapin E.A., Luna G., et al. The fate of Müller's glia following experimental retinal detachment: nuclear migration, cell division, and subretinal glial scar formation. Mol Vis 2010, 16:1361-1372.
63. Lim A.K.E., Alexander S.M., Lim K.S. Combined large radial retinotomy and circumferential retinectomy in the management of advanced proliferative vitreoretinopathy. Retina 2009, 29:112-116.
64. Limb G.A., Little B.C., Meager A., et al. Cytokines in proliferative vitreoretinopathy. Eye (Lond) 1991, 5(Pt 6):686-693.
65. Linsenmeier R.A., Padnick-Silver L. Metabolic dependence of photoreceptors on the choroid in the normal and detached retina. Invest Ophthalmol Vis Sci 2000, 41:3117-3123.
66. Lo A.C.Y., Woo T.T.Y., Wong R.L.M., et al. Apoptosis and other cell death mechanisms after retinal detachment: implications for photoreceptor rescue. Ophthalmologica 2011, 226(Suppl 1):10-17.
67. Machemer R., Aaberg T.M., Freeman H.M., et al. An updated classification of retinal detachment with proliferative vitreoretinopathy. Am J Ophthalmol 1991, 112:159-165.
68. Machemer R., Laqua H. Pigment epithelium proliferation in retinal detachment (massive periretinal proliferation). Am J Ophthalmol 1975, 80:1-23.
69. Machemer R. Pathogenesis and classification of massive periretinal proliferation. Br J Ophthalmol 1978, 62:737-747.
70. Mandelcorn M.S., Machemer R., Fineberg E., et al. Proliferation and metaplasia of intravitreal retinal pigment epithelium cell autotransplants. Am J Ophthalmol 1975, 80:227-237.
71. Mervin K., Valter K., Maslim J., et al. Limiting photoreceptor death and deconstruction during experimental retinal detachment: the value of oxygen supplementation. Am J Ophthalmol 1999, 128:155-164.
72. Miller B., Miller H., Patterson R., et al. Retinal wound healing. Cellular activity at the vitreoretinal interface. Arch Ophthalmol 1986, 104:281-285.
73. Mueller-Jensen K., Machemer R., Azarnia R. Autotransplantation of retinal pigment epithelium in intravitreal diffusion chamber. Am J Ophthalmol 1975, 80(3 Pt 2):530-537.
74. Mukherjee S., Guidry C. The insulin-like growth factor system modulates retinal pigment epithelial cell tractional force generation. Invest Ophthalmol Vis Sci 2007, 48:1892-1899.
75. Nagasaki H., Shinagawa K., Mochizuki M. Risk factors for proliferative vitreoretinopathy. Prog Retin Eye Res 1998, 17:77-98.
76. Nakazawa T., Matsubara A., Noda K., et al. Characterization of cytokine responses to retinal detachment in rats. Mol Vis 2006, 12:867-878.
77. Oshika T. Aqueous protein concentration in rhegmatogenous retinal detachment. Jpn J Ophthalmol 1990, 34:63-71.
78. Oshima Y., Sakamoto T., Hisatomi T., et al. Gene transfer of soluble TGF-beta type II receptor inhibits experimental proliferative vitreoretinopathy. Gene Ther 2002, 9:1214-1220.
79. Pastor J.C., La Rúa de E.R., Martín F. Proliferative vitreoretinopathy: risk factors and pathobiology. Prog Retin Eye Res 2002, 21:127-144.
80. Rachal W.F., Burton T.C. Changing concepts of failures after retinal detachment surgery. Arch Ophthalmol 1979, 97:480-483.
81. Rasier R., Gormus U., Artunay O., et al. Vitreous levels of VEGF, IL-8, and TNF-alpha in retinal detachment. Curr Eye Res 2010, 35:505-509.
82. Ricker L.J.A.G., Kijlstra A., de Jager W., et al. Chemokine levels in subretinal fluid obtained during scleral buckling surgery after rhegmatogenous retinal detachment. Invest Ophthalmol Vis Sci 2010, 51:4143-4150.
83. Ricker L.J.A.G., Kijlstra A., Kessels A.G.H., et al. Interleukin and growth factor levels in subretinal fluid in rhegmatogenous retinal detachment: a case-control study. PLoS One 2011, 6:e19141.
84. Rojas J., Fernandez I., Pastor J.C., et al. A strong genetic association between the tumor necrosis factor locus and proliferative vitreoretinopathy: the retina 4 project. Ophthalmology 2010, 117:2417-2423.e1-2.
85. Rojas J., Fernandez I., Pastor J.C., et al. Development of predictive models of proliferative vitreoretinopathy based on genetic variables: the Retina 4 project. Invest Ophthalmol Vis Sci 2009, 50:2384-2390.
86. Roldán-Pallarès M., Musa A.-S., Bravo-Llatas C., et al. Preoperative duration of retinal detachment and subretinal immunoreactive endothelin-1: repercussion on logarithmic visual acuity. Graefes Arch Clin Exp Ophthalmol 2010, 248:21-30.
87. Roldán-Pallarés M., Sadiq-Musa A., Rollin R., et al. Retinal detachment: visual acuity and subretinal immunoreactive endothelin-1. J Fr Ophtalmol 2008, 31:36-41.
88. Ryan S.J. The pathophysiology of proliferative vitreoretinopathy in its management. Am J Ophthalmol 1985, 100:188-193.
89. Scott I.U., Flynn H.W., Murray T.G., et al. Outcomes of surgery for retinal detachment associated with proliferative vitreoretinopathy using perfluoro-n-octane: a multicenter study. Am J Ophthalmol 2003, 136:454-463.
90. Sethi C.S., Lewis G.P., Fisher S.K., et al. Glial remodeling and neural plasticity in human retinal detachment with proliferative vitreoretinopathy. Invest Ophthalmol Vis Sci 2005, 46:329-342.
91. Sheridan C.M., Magee R.M., Hiscott P.S., et al. The role of matricellular proteins thrombospondin-1 and osteonectin during RPE cell migration in proliferative vitreoretinopathy. Curr Eye Res 2002, 25:279-285.
92. The classification of retinal detachment with proliferative vitreoretinopathy. Ophthalmology 1983, 90:121-125. The Retina Society Terminology Committee.
93. Wallace G.R., Curnow S.J., Wloka K., et al. The role of chemokines and their receptors in ocular disease. Prog Retin Eye Res 2004, 23:435-448.
94. Wang C.-H., Wang W.-T., Cheng S.-Y., et al. Leptin and interleukin-1beta modulate neuronal glutamate release and protect against glucose-oxygen-serum deprivation. Curr Neurovasc Res 2010, 7:223-237.
95. Wang S., Linsenmeier R.A. Hyperoxia improves oxygen consumption in the detached feline retina. Invest Ophthalmol Vis Sci 2007, 48:1335-1341.
96. Weller M., Heimann K., Wiedemann P. The pathogenesis of vitreoretinal proliferation and traction: a working hypothesis. Med Hypotheses 1990, 31:157-159.
97. Weller M., Wiedemann P., Heimann K. Proliferative vitreoretinopathy-is it anything more than wound healing at the wrong place?. Int Ophthalmol 1990, 14:105-117.
98. Wickham L., Charteris D.G. Glial cell changes of the human retina in proliferative vitreoretinopathy. Dev Ophthalmol 2009, 44:37-45.
99. Wickham L., Lewis G.P., Charteris D.G., et al. Histological analysis of retinas sampled during translocation surgery: a comparison with normal and transplantation retinas. BrJOphthalmol 2009, 93:969-973.
100. Wiedemann P., Weller M. The pathophysiology of proliferative vitreoretinopathy. Acta Ophthalmol 1988, 189(Suppl):3-15.
101. Wiedemann P. Growth factors in retinal diseases: proliferative vitreoretinopathy, proliferative diabetic retinopathy, and retinal degeneration. Surv Ophthalmol 1992, 36:373-384.
102. Yamamoto T., Akabane N., Takeuchi S. Vitrectomy for diabetic macular edema: the role of posterior vitreous detachment and epimacular membrane. Am J Ophthalmol 2001, 132:369-377.
103. Yamana T., Ozaki S., Negi A., et al. The process of closure of experimental retinal holes in rabbit eyes. Graefes Arch Clin Exp Ophthalmol 2000, 238:81-87.
104. Yang C.M., Cousins S.W. Quantitative assessment of growth stimulating activity of the vitreous during PVR. Invest Ophthalmol Vis Sci 1992, 33:2436-2442.
105. Yeung L., Yang K.-J., Chen T.-L., et al. Association between severity of vitreous haemorrhage and visual outcome in primary rhegmatogenous retinal detachment. Acta Ophthalmol 2008, 86:165-169.